Hosted on MSN
Novo Nordisk and Hims & Hers Health resolve patent dispute and collaborate on weight loss medicationsNovo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...
Hims & Hers (HIMS) stock jumped 49% in five days after FDA announced peptide review and company settled dispute with Novo ...
The Novo Nordisk partnership legitimizes Hims & Hers’ business model by replacing compounded GLP-1 sales with branded Wegovy and Ozempic distribution. Hims generated $2.35B revenue in 2025 (+59% YoY) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results